The government is leveraging its access to big data in order to aggressively pursue healthcare investigations. Maria Durant and Gejaa Gobena, partners in our Boston and Washington, D.C. offices, discuss the steps life sciences companies need to take to identify high-risk areas of their business before a potential investigation.
Press CTRL+C to copy embed code to clipboard